Browsing by Author "Zubieta, Marcela"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Consenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Parte II: Guía clínica chilena de Prevención de Infecciones Asociadas al Uso de Terapias Biológicas (PREVITEB)
    (2019) Cerón Araya, Inés María; Vizcaya Altamirano, María Cecilia; Gambra, Pilar; Ferres Garrido, Marcela Viviana; Bidart, Teresa; Lépez Quizhpi,Tania Lorena; Acuña, María Paz; Álvarez, Ana María; Zubieta, Marcela; Durán, Luisa; Rabagliati Borie, Ricardo Miguel
    The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of 2 manuscripts. This second part is a guideline that details these recommendations through screening strategies, prophylactic therapies and vaccines indications for bacterial, mycobacterial, viral, fungal and parasitic infections, both for adults and children.
  • Thumbnail Image
    Item
    Risk Factors Associated With Invasive Fungal Disease in Children With Cancer and Febrile Neutropenia A Prospective Multicenter Evaluation
    (LIPPINCOTT WILLIAMS & WILKINS, 2010) Villarroel, Milena; Aviles, Carmen L.; Silva, Pamela; Guzman, Ana M.; Poggi, Helena; Alvarez, Ana M.; Becker, Ana; O'Ryan, Miguel; Salgado, Carmen; Topelberg, Santiago; Tordecilla, Juan; Varas, Monica; Viviani, Tamara; Zubieta, Marcela; Santolaya, Maria E.
    Background: Empiric antifungal treatment has become standard of care in children with cancer and prolonged fever and febrile neutropenia (FN), with the downside that it leads to significant over treatment. We characterized epidemiologic, clinical, and laboratory features of invasive fungal disease (IFD) in children with cancer and FN with the aim to identify risk factors for IFD that can aid in better selecting children who require antifungal treatment.